EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypertriglyceridemia Therapy: Past, Present and Future Perspectives

Ileana Canfora iD, Sabata Pierno

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179727 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ileana Canfora und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari "Aldo Moro", 70121 Bari, Italy. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Hypolipidemic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertriglyceridemia therapy is essential for preventing cardiovascular diseases. Fibrates belong to an important class of lipid-lowering drugs useful for the management of dyslipidaemia. By acting on the peroxisome proliferator-activated receptor (PPAR)-α, these drugs lower serum triglyceride levels and raise high-density lipoprotein cholesterol. Fibrate monotherapy is associated with a risk of myopathy and this risk is enhanced when these agents are administered together with statins. However, whereas gemfibrozil can increase plasma concentrations of statins, fenofibrate has less influence on the pharmacokinetics of statins. Pemafibrate is a new PPAR-α-selective drug considered for therapy, and clinical trials are ongoing. Apart from this class of drugs, new therapies have emerged with different mechanisms of action to reduce triglycerides and the risk of cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaHypolipidemic AgentsHumansFibric AcidsPPAR alphaAnimalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesGemfibrozilTriglycerides

Stichwörter der Autor:innen

cardiovascular diseasefibrateshypertriglyceridemialipid-lowering drugspharmacotherapy

Substanzen

Hypolipidemic AgentsFibric AcidsPPAR alphaHydroxymethylglutaryl-CoA Reductase InhibitorsGemfibrozilTriglycerides

Autor:innen und Institutionen

  • Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari "Aldo Moro", 70121 Bari, Italy.

ORCID-Profile: Ileana Canfora

Zitieren

APA

Canfora, I., & Pierno, S. (2024). Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179727

Vancouver

Canfora I, Pierno S. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179727

BibTeX
@article{Canfora2024,
  author = {Canfora, Ileana and Pierno, Sabata},
  title = {Hypertriglyceridemia Therapy: Past, Present and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179727}
}
Kostenlos starten →